Eledon Pharmaceuticals, Inc. (ELDN)
ELDN Stock Price Chart
Explore Eledon Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze ELDN price movements and trends.
ELDN Company Profile
Discover essential business fundamentals and corporate details for Eledon Pharmaceuticals, Inc. (ELDN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
17 Sept 2014
Employees
31.00
Website
https://eledon.comCEO
David-Alexandre C. Gros
Description
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
ELDN Financial Timeline
Browse a chronological timeline of Eledon Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 May 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$0.22.
Earnings released on 14 Aug 2025
EPS came in at -$0.13 surpassing the estimated -$0.23 by +43.48%.
Earnings released on 14 May 2025
EPS came in at -$0.08 surpassing the estimated -$0.28 by +71.43%.
Earnings released on 20 Mar 2025
EPS came in at -$0.64 falling short of the estimated -$0.32 by -100.00%, while revenue for the quarter reached $192.00K .
Earnings released on 12 Nov 2024
EPS came in at -$0.32 falling short of the estimated -$0.30 by -6.67%.
Earnings released on 19 Aug 2024
EPS came in at -$0.32 falling short of the estimated -$0.31 by -3.23%.
Earnings released on 9 May 2024
EPS came in at -$0.34 surpassing the estimated -$0.37 by +8.11%.
Earnings released on 28 Mar 2024
EPS came in at -$0.29 surpassing the estimated -$0.38 by +23.68%, while revenue for the quarter reached $560.00K .
Earnings released on 9 Nov 2023
EPS came in at -$0.35 surpassing the estimated -$0.41 by +14.63%.
Earnings released on 10 Aug 2023
EPS came in at -$0.40 surpassing the estimated -$0.47 by +14.89%.
Earnings released on 11 May 2023
EPS came in at -$0.75 falling short of the estimated -$0.71 by -5.63%.
Earnings released on 30 Mar 2023
EPS came in at -$0.68 surpassing the estimated -$0.70 by +2.86%.
Earnings released on 14 Nov 2022
EPS came in at -$0.73 falling short of the estimated -$0.68 by -7.35%.
Earnings released on 11 Aug 2022
EPS came in at -$0.65 surpassing the estimated -$0.72 by +9.72%.
Earnings released on 12 May 2022
EPS came in at -$0.69 falling short of the estimated -$0.67 by -2.99%.
Earnings released on 24 Mar 2022
EPS came in at -$0.59 surpassing the estimated -$0.83 by +28.92%, while revenue for the quarter reached $120.00 .
Earnings released on 11 Nov 2021
EPS came in at -$0.66 surpassing the estimated -$0.67 by +1.49%.
Earnings released on 12 Aug 2021
EPS came in at -$0.50 surpassing the estimated -$0.58 by +13.79%.
Earnings released on 13 May 2021
EPS came in at -$0.57 falling short of the estimated -$0.37 by -54.05%.
Earnings released on 30 Mar 2021
EPS came in at -$2.12 falling short of the estimated -$1.39 by -52.52%, while revenue for the quarter reached $120.00K .
Earnings released on 16 Nov 2020
EPS came in at -$5.51 falling short of the estimated -$1.75 by -214.86%, while revenue for the quarter reached $120.00K .
Stock split effective on 5 Oct 2020
Shares were split 1 : 18 , changing the number of shares outstanding and the price per share accordingly.
ELDN Stock Performance
Access detailed ELDN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.